Debio 1143-106- A Smac Mimetic In Combination With Nivolumab In Patients Failing Prior Pd-1/Pd-L1 Treatment
Posted Date: Dec 30, 2019
- Investigator: Shuchi Gulati
- Specialties: Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Oncology, Ovarian Cancer, Pancreatic Cancer
- Type of Study: Drug
The purpose of this study is to determine overall safety/tolerability and PK by optimizing doses of Debio 1143 when combined with the standard dose of nivolumab, as well as treatment compliance in patients with advanced solid malignancies who failed prior systemic standard treatments.
Criteria:
To Be Eligible: >18 Years Of Age, Confirmed Advanced/ Unresectable Or Metastatic Solid Tumor Dx, At Least 1 Prior Line Of Chemo, No Liver Cirrhosis, No Known Uncontrolled Cardiac History, Medical Diagnosis, Or Active Infection Interfering With Study Resul
Keywords:
Cancer, Phase 1
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com